Navigation Links
Sleeping pills reversly push to vegitative state

Zolpidem is usually used to treat insomnia. The effects of zolpidem on three patients were studied for a period of six months by South African researchers//. Neurological rehabilitation experts reveal that they are in a condition where keeping eyes open, awake but unaware of the surroundings, no interaction and responses, having signs of movement, sleep and breathing called vegetative state.

Zolpidem was given to the patients every morning.

An improvement was seen within 20 minutes of taking the drug, where out of the three patients (A,B,C), patient A was able to speak and reply to questions, patient B with the same changes and even catches a basketball whereas patient C after constant screaming was able to watch TV and give responses.

Dr Clauss, a co-worker said drugs like Zolpidem activate receptors in nerve cells in the brain for GABA.

This drug reshapes the damaged receptors and triggers nerve cell activity.

Mike Barnes, professor of neurological rehabilitation at the Hunters Moor centre in Newcastle, said it was possible that the patients had not had ‘true’ PVS means the patient should not wake up and respond.

But if they was no PVS, it would be a remarkable finding, and certainly worth further research.


'"/>




Page: 1

Related medicine news :

1. Sleeping sickness - a silent killer
2. Help For Kids With Difficulty In Sleeping
3. Sleeping Less May be related to Weight Gain
4. Sleeping Boy Does A Rip Van Winkle
5. With New Drug To Fight Against Sleeping, Your Increment Is Not Far Away
6. Uganda Reports Failure To Contain Sleeping Sickness
7. Fluorescent markers to distinguish Trypanosoma brucei strains causing Sleeping Sickness
8. Sleeping Is No Mean Art … It Is A Privilege Denied To Many
9. Toddlers Have Respiratory Trouble When Sleeping With Their Face Up
10. Sleeping disorder risk factor for heart attacks
11. Newer Generation Sleeping Pills Lack Superior Performance
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Military Officers Association of America (MOAA) announced ... Veterans Affairs, retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the ... an intimacy with the issues and challenges veterans face with the VA. Following a ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... The Aesthetic ... facelift . Dr. Talei has come up with a proprietary technique that he calls ... lifts tissues that have dropped. For all ages, patients can expect to look refreshed, ...
(Date:6/23/2017)... Santa Monica, CA (PRWEB) , ... June 23, 2017 , ... ... PureLife as the endorsed amalgam separator supplier for CDA members. As part of the ... a reduced price of $99, saving more than $400 off the retail value. This ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... ALTO, Calif. , June 9, 2017 ... device company focused on the design, manufacture, sale and ... the market on the progress of its commercial roll-out ... is now available in more than one hundred (100) ... AeroForm offers a needle-free alternative for ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... -- Eli Lilly and Company (NYSE: LLY ... 3 MONARCH 2 study showed that abemaciclib, a ... with fulvestrant, significantly improved progression-free survival (PFS) compared ... hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative ... progressed after endocrine therapy (median PFS, 16.4 vs. ...
Breaking Medicine Technology: